Exact Sciences will be sharing results for its multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Special Conference taking place Nov. 13-16 in San Diego, the company announced today.

According to a release, key findings include enhanced early-stage detection via a multi-biomarker approach, which showed 28% improved sensitivity for stage 1 cancers and projected a 42% reduction in Stage IV cases over 10 years. The DETECT-A study also indicated that MCED testing supports lung cancer screening without affecting adherence to standard care, potentially lowering cancer mortality by 17% over a decade.

“We believe MCED testing is our single biggest opportunity to combat these stark statistics, and the Exact Sciences team is committed to taking a rigorous, comprehensive approach to multi-cancer screening,” Exact Sciences Chief Medical Officer and Vice President of Multi-Cancer Early Detection Tom Beer, M.D., said in a statement. “The new data answer key questions about the impact we can anticipate with MCED testing if integrated into clinical practice.”

This new research will help inform the final design of Exact Sciences’ Cancerguard test, which is currently being developed.